IgA 肾病

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14.

• 摘要

Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21.

• 摘要

Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60.

• 摘要

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012 Jun;2(2):139-274.

• 全文

Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42.

• 摘要

Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.

• 全文
• 摘要

Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68.

• 摘要

Yeo SC, Liew A, Barratt J. Emerging therapies in immunoglobulin A nephropathy. Nephrology (Carlton). 2015 Nov;20(11):788-800.

• 全文
• 摘要

1.  Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013 Jun 20;368(25):2402-14.

• 摘要

2.  Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009 Sep;76(5):534-45.

• 摘要

3.  Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012 Nov;60(5):812-20.

• 摘要

4.  Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014 Oct;86(4):828-36.

• 全文
• 摘要

5.  Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011 Aug;80(3):310-7.

• 摘要

6.  Trimarchi H, Barratt J, Cattran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017 May;91(5):1014-21.

• 摘要

7.  Haas M, Verhave JC, Liu ZH, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):691-701.

• 摘要

8.  Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2088-97.

• 摘要

9.  Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002 Sep 5;347(10):738-48.

• 摘要

10.  Galla JH. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377-87.

• 摘要

11.  Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997 Jun;29(6):829-42.

• 摘要

12.  Iseki K, Miyasoto F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int. 2004 Sep;66(3):914-9.

• 摘要

13.  Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004 Sep;66(3):920-3.

• 摘要

14.  Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 2003 Jun;63(6):2286-94.

• 摘要

15.  Waldherr R, Rambausek M, Duncker D, et al. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant. 1989;4(11):943-6.

• 摘要

16.  Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000 Nov;26(3):354-7.

• 摘要

17.  Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006 Dec;79(6):1130-4.

• 全文
• 摘要

18.  Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007 Aug;18(8):2408-15.

• 全文
• 摘要

19.  Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant. 2007 Mar;22(3):772-7.

• 全文
• 摘要

20.  Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol Dial Transplant. 2013 Dec;28(12):2946-60.

• 全文
• 摘要

21.  Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6):e1002765.

• 全文
• 摘要

22.  Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Mar 13;43(4):321-7.

• 全文
• 摘要

23.  Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010 Oct;21(10):1791-7.

• 全文
• 摘要

24.  Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014 Nov;46(11):1187-96.

• 全文
• 摘要

25.  Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant. 1999 Oct;14(10):2279-82.

• 摘要

26.  Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis. 1987 Mar;9(3):183-90.

• 摘要

27.  Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy - a post-mortem study. Nephrol Dial Transplant. 1995;10(1):35-8.

• 摘要

28.  Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol. 1992 Aug;38(2):61-8.

• 摘要

29.  Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med. 1992 Sep 3;327(10):702-6.

• 全文
• 摘要

30.  Meadow SR, Scott DG. Berger disease: Henoch-Schönlein syndrome without the rash. J Pediatr. 1985 Jan;106(1):27-32.

• 摘要

31.  Tomino Y. Pathogenesis of IgA nephropathy. Contrib Nephrol. 2007;157:1-7.

• 摘要

32.  Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999 Jul;104(1):73-81.

• 摘要

33.  Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011 Jul;31(4):349-60.

• 摘要

34.  D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000 Aug;36(2):227-37.

• 摘要

35.  Brenner BM, Levine SA. Brenner and Rector's the kdney. 7th ed. Boston, MA: Saunders; 2007:3072.

36.  Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005 Sep-Oct;18(5):503-12.

• 摘要

37.  Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001 Apr 15;110(6):434-7.

• 摘要

38.  Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004 May;24(3):197-217.

• 摘要

39.  Davin JC, Ten Berge IT, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int. 2001 Mar;59(3):823-34.

• 摘要

40.  Hasbargen JA, Copley JB. Utility of skin biopsy in the diagnosis of IgA nephropathy. Am J Kidney Dis. 1985 Aug;6(2):100-2.

• 摘要

41.  Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012 May;81(9):833-43.

• 摘要

42.  Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol. 2013 Jun;9(6):320-27.

• 摘要

43.  Rosselli JL, Thacker SM, Karpinski JP, et al. Treatment of IgA nephropathy: an update. Ann Pharmacother. 2011 Oct;45(10):1284-96.

• 摘要

44.  Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun;69(11):1939-44.

• 摘要

45.  Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006 Jun;69(11):1934-8.

• 摘要

46.  Praga M, Gutiérrez E, González E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003 Jun;14(6):1578-83.

• 摘要

47.  Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001 Jul;38(1):18-25.

• 摘要

48.  Liu LL, Wang LN, Liu LL, et al. Omega-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012 Feb;77(2):119-25.

• 摘要

49.  Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012 Jun;2(2):139-274.

• 全文

50.  Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999 Mar 13;353(9156):883-7.

• 摘要

51.  Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004 Jan;15(1):157-63.

• 摘要

52.  Lv J, X, Wang H. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012 Jun;23(6):1108-16.

• 摘要

53.  Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017 Aug 1;318(5):432-42.

• 摘要

54.  Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004 Apr;65(4):1135-44.

• 摘要

55.  Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD003962.

• 摘要

56.  Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27(2):170-75.

• 摘要

57.  Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001 Oct;38(4):736-43.

• 摘要

58.  Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015 Dec 3;373(23):2225-36.

• 全文
• 摘要

59.  Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol. 2004 May;24(3):256-68.

• 摘要

60.  Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002 Jan;13(1):142-8.

• 摘要

61.  Smerud HK, Bárány P, Lindström K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011 Oct;26(10):3237-42.

• 全文
• 摘要

62.  Yeo SC, Liew A, Barratt J. Emerging therapies in immunoglobulin A nephropathy. Nephrology (Carlton). 2015 Nov;20(11):788-800.

• 全文
• 摘要

63.  Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-27.

• 摘要

64.  ClinicalTrials.gov. BRIGHT-SC: blisibimod response in IgA nephropathy following at-home treatment by subcutaneous administration. Sep 2017 [internet publication].

• 全文

65.  Kim MJ, McDaid JP, McAdoo SP, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol. 2012 Oct 1;189(7):3751-8.

• 全文
• 摘要

66.  ClinicalTrials.gov. Safety and efficacy study of fostamatinib to treat immunoglobin A (IgA) nephropathy. Aug 2017 [internet publication].

• 全文

67.  Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017 Apr;28(4):1306-13.

• 摘要

68.  Coppo R, Camilla R, Alfarano A, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009 Mar;75(5):536-41.

• 摘要

69.  ClinicalTrials.gov. Pilot study of Velcade® in IgA nephropathy. Aug 2017 [internet publication].

• 全文

70.  Beerman I, Novak J, Wyatt RJ, et al. The genetics of IgA nephropathy. Nat Clin Pract Nephrol. 2007 Jun;3(6):325-38.

• 摘要